Unique ID issued by UMIN | UMIN000009811 |
---|---|
Receipt number | R000011096 |
Scientific Title | Comparison of randomized trials of antibiotic combination therapies for patients with ulcerative colitis |
Date of disclosure of the study information | 2013/01/21 |
Last modified on | 2018/11/13 09:46:59 |
Comparison of randomized trials of antibiotic combination therapies for patients with ulcerative colitis
Antibiotics trials for ulcerative colitis
Comparison of randomized trials of antibiotic combination therapies for patients with ulcerative colitis
Antibiotics trials for ulcerative colitis
Japan |
Ulcerative colitis
Gastroenterology | Gastrointestinal surgery |
Others
NO
A randomized controlled trial comparing two antibiotic regimens for ulcerative colitis
Safety,Efficacy
Confirmatory
Explanatory
Phase III
Clinical remission and clinical response
Treatment failure rate
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Active
YES
NO
Institution is not considered as adjustment factor.
YES
Central registration
2
Treatment
Medicine |
One group is to receive two-week combination therapy consisting of amoxicillin (Sawacillin) 500 mg t.i.d, tetracycline (Acromycin) 500 mg t.i.d, and metronidazole (Flagyl) 250 mg t.i.d. with an inhibitor of gastric acid secretion. Patients are to be followed for 3 months (first endpoint).
Another group will receive two week combination therapy consisting of amoxicillin (Sawacillin) 500 mg t.i.d, fosfomycin (Fosmicin) 1000mg t.i.d, and metrozole (Flagyl) 250 mg t.i.d, with an inhibitor of gastric acid secretion. Patients are to be followed for 3 months.
16 | years-old | <= |
75 | years-old | >= |
Male and Female
1) Eligibility criteria for study entry are mild-to-severe, chronically relapsing UC and a Lichtiger Clinical Activity Index of at least 6 or a Mayo score of more than 5.
2) Patients able to visit the hospital during follow up
3) Cases whose doctors decided that they would be able to provide adequate answers during an interview
4) Patients providing informed consent.
1) Patients with diarrhea and fever, unable take the medications and those with toxic megacolon
2) Patients allergic to penicillin
3) Patients allergic to SASP and 5-ASA
4) Pregnant patients. Cases with complications of other severe diseases, such as renal and hepatic disorders.
5) Patients with mental disorders, and so on, considered by their doctors to be unsuitable candidates for clinical trials
40
1st name | |
Middle name | |
Last name | Kimitoshi Kato |
Nihon University School of Medicine, Itabshi Hospital
Division of Research Planning and Development
30-1 Oyaguchi-Kami machi, Itabashi-ku, Tokyo
03-3972-8111
katou.kimitoshi@nihon-u.ac.jp
1st name | |
Middle name | |
Last name | Kimitoshi Kato |
Nihon University School of Medicine, Itabshi Hospital
Division of General Medicine, Dept. of Internal Medicine
30-1 Oyaguchi-Kami machi, Itabashi-ku, Tokyo
03-3972-8111
katou.kimitoshi@nihon-u.ac.jp
Division of General Medicine, Department of Internal Medicine, Nihon University School of Medicine
Division of General Medicine, Department of Internal Medicine, Nihon University School of Medicine
Other
Japan
NO
日本大学医学部附属板橋病院
2013 | Year | 01 | Month | 21 | Day |
Unpublished
Terminated
2012 | Year | 12 | Month | 17 | Day |
2013 | Year | 01 | Month | 23 | Day |
2018 | Year | 08 | Month | 30 | Day |
2018 | Year | 12 | Month | 30 | Day |
2018 | Year | 12 | Month | 30 | Day |
2019 | Year | 03 | Month | 20 | Day |
2013 | Year | 01 | Month | 19 | Day |
2018 | Year | 11 | Month | 13 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011096